Avalo Therapeutics (AVTX) Assets Average (2015 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Assets Average data on file, last reported at $108.2 million in Q1 2026.

• Quarterly Assets Average fell 25.21% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (down 25.21% YoY) and the FY2025 annual result came in at $133.6 million, up 55.59% from the prior year.
• Assets Average fell to $108.2 million in Q1 2026, from $120.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $144.6 million in Q1 2025 to a low of $25.1 million in Q4 2023.
• A 5-year average of $79.6 million and a median of $72.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average slumped 60.18% — and 2024, when it soared 395.77%.
• Tracing AVTX's Assets Average over 5 years: stood at $35.0 million in 2022, then decreased by 28.11% to $25.1 million in 2023, then jumped by 395.77% to $124.6 million in 2024, then fell by 3.06% to $120.8 million in 2025, then declined by 10.44% to $108.2 million in 2026.
• The last three Assets Average figures came in at $108.2 million (Q1 2026), $120.8 million (Q4 2025), and $125.8 million (Q3 2025), per Business Quant data.